Artivion (AORT) Stock News

Artivion (NYSE:AORT) presented late-breaking data from the AMDS PERSEVERE and PROTECT trials at the 39th EACTS Annual Meeting on October 13, 2025. The PERSEVERE 30-day analysis (n=40 with organ malperfusion) showed visceral malperfusion resolution in 83% and renal malperfusion resolution in 74%, with radiographic renal resolution in all affected patients. The PROTECT real-world registry (n=141) reported outcomes consistent with PERSEVERE and DARTS, including renal failure requiring dialysis 4.2%, unanticipated reoperation 1.4%, no paralysis/paraparesis, and 95.3–100% positive aortic remodeling in zones 1–3.

Artivion (NYSE:AORT), a cardiac and vascular surgery company specializing in aortic disease, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will engage in a fireside chat on September 10, 2025, at 2:35 pm ET at the Sheraton New York Times Square Hotel.

Investors can access the live webcast through Artivion's website at www.artivion.com in the Investors section. The webcast recording will remain available for 90 days following the presentation.

Artivion (NYSE:AORT) reported strong Q2 2025 financial results with revenue reaching $113.0 million, marking a 15% increase from Q2 2024. The company achieved net income of $1.3 million ($0.03 per share) and non-GAAP net income of $10.7 million ($0.24 per share).

Key highlights include 33% growth in Adjusted EBITDA to $24.8 million, significant revenue growth across product lines with On-X and stent grafts both up 24%, and the exchange of $99.5 million in convertible senior notes for common stock. The company received FDA IDE approval for the ARTIZEN pivotal trial for Arcevo LSA.

Given strong performance, Artivion raised its 2025 guidance, now expecting constant currency growth of 12-14% with revenues between $435-443 million and adjusted EBITDA growth of 21-28% ($86-91 million).

Artivion (NYSE:AORT), a cardiac and vascular surgery company, announced its participation in two upcoming investor conferences. The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 10:30 a.m. ET, with a live webcast available on their website. Additionally, management will participate in investor meetings at the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 12, 2025, though no webcast will be available for this event.

Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close.

The company will host a teleconference call and live webcast at 4:30 p.m. ET featuring CEO Pat Mackin, followed by a Q&A session. Participants can dial 862-298-0702 to join the call, with replay available at 877-660-6853 or 201-612-7415 using conference number 13754541.

The webcast and earnings press release will be accessible through the Investors section of www.artivion.com.

Artivion (NYSE: AORT), a cardiac and vascular surgery company specializing in aortic disease, has announced its participation in two upcoming investor conferences. The company will present at the Truist Securities MedTech Conference on June 17, 2025, at 8:00 a.m. ET at the InterContinental Boston Hotel, with a live webcast available on their website www.artivion.com. The webcast recording will be accessible for 90 days afterward. Additionally, Artivion's management team will participate in investor meetings at the Citizens Medical Devices and Healthcare Services Forum on the same day, though no webcast will be available for this event due to its format.

Artivion (NYSE: AORT) has successfully closed transactions to exchange approximately $99.54 million of its 4.250% Convertible Senior Notes due 2025 for 4,334,347 shares of common stock. The company also made a cash payment of $1.7 million for accrued and unpaid interest to the note holders. Following these transactions, only $0.46 million in aggregate principal amount of the Notes remains outstanding.

CEO Pat Mackin emphasized that this effective retirement of convertible notes represents a significant milestone in strengthening Artivion's financial position, reducing leverage ratios, and enhancing balance sheet flexibility. J. Wood Capital Advisors LLC served as financial advisor for these exchange transactions.

Artivion (NYSE: AORT) has announced private exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. The company will repurchase approximately $95 million in principal amount of existing convertible notes in exchange for common stock. Based on the May 13 closing price of $28.91 per share, the exchange would result in the issuance of approximately 4.1 million shares. The company will also pay cash for accrued and unpaid interest. The exchange transactions are expected to close around May 28, 2025, subject to customary closing conditions. J. Wood Capital Advisors LLC served as financial advisor for the transaction.

Artivion (NYSE: AORT) reported its Q1 2025 financial results, showing revenue of $99.0 million, up 2% YoY (4% on constant currency). The company experienced strong product growth with stent grafts up 14%, On-X up 10%, and BioGlue up 7% YoY. However, preservation services declined 23% due to a cybersecurity incident. Q1 resulted in a net loss of $(0.5) million or $(0.01) per share, while adjusted EBITDA increased 1% to $17.5 million. Notably, Endospan's NEXUS TRIOMPHE IDE trial showed promising results with a 63% reduction in major adverse events. Artivion raised its 2025 revenue guidance to $423-435 million, projecting 11-14% growth, and expects adjusted EBITDA of $84-91 million, representing 18-28% growth.